ArticleJournal of gastrointestinal cancer2026
Prognostic and Treatment-Associated Survival Effects of Microsatellite Instability Across Disease Stages in Colon Cancer: An NCDB Analysis.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicrosatellite instability (MSI) is an established molecular biomarker in colorectal cancer (CRC). However, its stage-specific prognostic value and treatment-modifying role in colon cancer remain incompletely defined, particularly across contemporary multimodality treatment strategies.
methodsWe conducted a retrospective cohort study using the National Cancer Database, including patients aged ≥ 20 years diagnosed with colon cancer between 2004 and 2020 with documented tumor stage and MSI status. MSI was categorized as microsatellite stable (MSS), MSI-low (MSI-L), or MSI-high (MSI-H). Multivariable Cox proportional hazards regression models were used to evaluate the association between MSI status and overall survival (OS), stratified by disease stage and treatment combinations. Patients who died within 90 days of diagnosis were excluded to minimize immortal-time bias.
resultsA total of 129,484 patients met inclusion criteria. MSI-H tumors comprised 16.8% of cases. The prognostic impact of MSI status varied by stage. MSI-H was not associated with OS in stage 0-I disease but conferred a significant survival advantage in stage II (HR 0.86, P < 0.001), stage III (HR 0.71, P < 0.001), and stage IV disease (HR 0.65, P < 0.001). MSI-L tumors demonstrated no consistent survival benefit, with a modest association observed only in stage IV (HR 0.89, P = 0.015). Treatment-stratified analyses revealed that in stage II disease, MSI-H was associated with improved survival only among patients treated with surgery alone (HR 0.83, P < 0.001). In contrast, MSI-H tumors demonstrated substantial survival benefit across multiple treatment pathways in stage III and IV disease, including surgery plus chemotherapy (stage III HR 0.72; stage IV HR 0.70) and immunotherapy-containing regimens (stage III HR 0.28; stage IV HR 0.47; all P < 0.01).
conclusionMSI status demonstrates a stage-dependent role in colon cancer, serving as a prognostic biomarker in early-stage disease and a predictive marker for immunotherapy-associated survival benefit in advanced stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.